Does anti-tumor necrosis factor (TNF) therapy for rheumatoid arthritis (RA) increase mortality rates in comparison to standard nonbiologic DMARD therapy?

Updated: Feb 07, 2020
  • Author: Howard R Smith, MD; Chief Editor: Herbert S Diamond, MD  more...
  • Print
Answer

A large national prospective cohort study over a mean of 4 years demonstrated that anti-TNF therapy for RA was not associated with a significant increase or decrease in mortality when compared with standard nonbiologic DMARD therapy. [125] The results from another study confirmed that the risk of serious infection and malignancy is not increased in patients receiving anti-TNF therapy when the patients have early RA and have not been previously treated with MTX or other DMARDs. [126]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!